Other Resource

GAIN: How a New Law is Stimulating the Development of Antibiotics

On July 9, 2012, the Generating Antibiotic Incentives Now, or GAIN, provisions were signed into law by President Barack Obama as part of the Food and Drug Administration Safety and Innovation Act. This bipartisan legislation extends by five years the exclusivity period during which certain antibiotics—those that treat serious or life-threatening infections—can be sold without generic competition. This additional period of exclusivity increases the potential for profits from new antibiotics by giving innovative companies more time to recoup their investment costs.

Why is this legislation needed?

Antibiotics are one of the greatest success stories in modern medicine. Although we associate them with treating acute infections, they make much of modern care possible—from routine surgical procedures to organ transplants and cancer treatment.

Yet the pipeline of new antibiotics is dwindling, and a global crisis looms. Drug-resistant bacteria are spreading in our hospitals and our communities. According to a 2013 report by the Centers for Disease Control and Prevention, or CDC, more than 2 million people a year are sickened by resistant infections, and more than 23,000 die as a result.

Just when we need innovation the most, the number of new drugs to replace ineffective antibiotics is not adequate to meet patients’ needs. As highlighted in a report funded by the Swedish government, many major pharmaceutical companies have abandoned their investment in developing new antibiotics and instead are focusing their resources on medicines with the potential of producing greater profits.

Bringing any new medicine to market costs hundreds of millions of dollars for basic and clinical research, including money spent on candidate drugs that do not pan out. Antibiotics generate small revenue compared with “blockbuster” drugs such as those for high blood pressure or cholesterol, which may be taken daily by millions of patients. Therefore, there is little incentive for manufacturers to develop new antibiotics.

GAIN seeks to increase antibiotics’ commercial value to manufacturers by extending the term of exclusivity, or market protection, granted by FDA to innovator drugs.

What does GAIN do?

Extends the Exclusivity for New Antibiotics

GAIN In Action 

GAIN grants an additional five years of exclusivity for those new antibiotics designated under the law as a “qualified infectious disease product,” defined as “an antibacterial or antifungal drug for human use intended to treat serious or life-threatening infections.” The extra five years of market protection is in addition to any existing exclusivity, including that which may be applicable under Hatch-Waxman (five years or three years), orphan drug (seven years), or pediatric exclusivity (six months).

Speeds Development and Review of New Antibiotics

Drugs that fall under the GAIN provisions receive fast track and priority review status and undergo an expedited regulatory approval process with FDA.

Requires Additional and/or Updated Clinical Trial Guidance

GAIN requires FDA to issue new guidance on the development of pathogen-focused antibiotics—those that target specific bacteria. Such advice has not been available previously, leaving drug makers with no clear development pathway for these products. The agency must also review and revise other antibiotic guidance to ensure that it is up-to-date from a scientific and regulatory perspective.

Requires Listing of Pathogens That Pose a Threat to Public Health

GAIN requires FDA to compile a list of “qualifying pathogens” that have the potential to pose a serious threat to public health and to update this list at least every five years. The agency must consult with CDC, medical care professionals, and clinical researchers in deciding which pathogens to include—taking into consideration the impact on human health and any increases in drug resistance.

Progress to date

 “Establishing new ways of developing safe and effective new antibacterial drugs is an enormous challenge and not an effort that can be accomplished alone.”
—Edward Cox, M.D., M.P.H., director of the Office of Antimicrobial Products in FDA’s Center for Drug Evaluation and Research, announcing the creation of the Antibacterial Drug Development Task Force under GAIN

As of October 2013, at least 16 antibiotics have been designated as qualified infectious disease products under GAIN, making them eligible for incentives such as added market protection if approved for patient use. Many of these antibiotics, however, are in the early stages of development and may not be approved for patients. However, two companies submitted marketing applications for qualified infectious disease products in late 2013 that could be eligible for approval as early as 2014.1

GAIN implementation is ongoing. To date, FDA has:

  • Created an Antibacterial Drug Development Task Force to develop and revise guidance for antibacterial drug development.
  • Released a draft list of pathogens with the potential to pose a serious threat to public health and the methodology used to generate the list.
  • Drafted preliminary guidance for companies developing antibiotics that address unmet needs, including drugs that are narrowly targeted or pathogen focused.
  • Reviewed and updated several antibacterial drug development guidance documents.

Although GAIN is an important first step in moving antibiotics safely and quickly from the laboratory to the patients who need them, the law cannot achieve that goal on its own. A new regulatory approval pathway for limited-population antibacterial drugs would encourage the development of antibiotics that address the greatest unmet needs of patients.

Learn about Pew’s advocacy for a limited-population antibacterial drug approval pathway.

Related Links

1Durata Therapeutics, Inc. “Durata Therapeutics Announces NDA Submission for Dalbavancin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections (ABSSSI),” GlobeNewswire.com (Sept. 26, 2013), accessed October 25, 2013, http://globenewswire.com/news-release/2013/09/26/576235/10050158/en/Durata-Therapeutics-Announces-NDA-Submission-for-Dalbavancin-for-the-Treatment-of-Patients-With-Acute-Bacterial-Skin-and-Skin-Structure-Infections-ABSSSI.html; Cubist Pharmaceuticals, Inc. “Cubist Announces Submission of New Drug Application for Investigational Antibiotic Tedizolid for Treatment of Serious Skin Infections,” Cubist.com (Sept. 22, 2013),  accessed October 25, 2013, http://investors.cubist.com/file.aspx?IID=4093793&FID=20265968.
Date added:
Nov 7, 2013

Related Resources

The Super Bugs Causing Unmet Need and the Drugs to Fight Them

Issue Brief

Testing new antibiotics to treat highly resistant bacterial infections is especially difficult, since only a small number of patients contract such infections or meet the requirements to participate in clinical trials. Following are examples of hard-to-treat pathogens that present the greatest unmet needs today, and the types of drugs that are most likely to address them.


Pew Testimony Before The President’s Council of Advisors on Science and Technology

Other Resource

The President’s Council of Advisors on Science and Technology held a public meeting on April 4 to discuss the issue of antimicrobial resistance. Drug safety and innovation director Elizabeth Jungman testified on the need to spur the development of new antibacterial drugs.


IDSA, Pew Support Regulatory Pathway for Antibiotic Development

Media Coverage
Today, Pew applauds increasing bipartisan support in Congress to spur antibiotic development and meet the needs of patients facing the growing threat of drug-resistant pathogens. More

Tracking the Pipeline of Antibiotics in Development

Other Resource

Drug-resistant bacteria, or superbugs, present a serious and worsening threat to human health. According to a Centers for Disease Control and Prevention report, 2 million Americans acquire serious infections caused by antibiotic-resistant bacteria each year, and 23,000 of them die. Doctors routinely encounter patients with infections that do not respond to available treatment, and when new drugs come to market, bacteria quickly develop resistance. To ensure that the supply of new antibiotics keeps pace with these evolving pathogens, it is necessary to have a robust pipeline of new drugs and innovative pathways to get this medicine to the patients who need it the most


From Lab Bench to Bedside: A Backgrounder on Drug Development

Other Resource

The process of creating new medicines is complex, time-consuming, and costly. Moving a potential therapy from concept to market can take between 10 and 15 years and cost developers as much as $1 billion. Indeed, industry also bears the cost of failure: For every drug that ultimately receives approval from the U.S. Food and Drug Administration, some 5,000 to 10,000 compounds don’t make it through the process.


Antibiotics Currently in Clinical Development

Other Resource
As of February 2014, there are at least 45 new antibiotics with the potential to treat serious bacterial infections in clinical development for the U.S. market. The success rate for drug development is low; at best, only 1 in 5 candidates that enter human testing will be approved for patients. This snapshot of the antibiotic pipeline will be updated periodically as products advance or are known to drop out of development. More

Pew, 31 Other Organizations Send Letter of Support for the ADAPT Act

Other Resource
The Pew Charitable Trusts sent a letter to Representatives Phil Gingrey (R-GA) and Gene Green (D-TX) of qualified support of the Antibiotic Development to Advance Patient Treatment (ADAPT) Act, a welcome step towards establishing a new regulatory pathway to bring desperately-needed antibiotics to the patients who need them most. The letter was also signed by 31 organizations representing healthcare providers, hospitals, pharmacists, clinical laboratory scientists and medical microbiologists, public health experts, patients and advocates. More

'ADAPT': A Regulatory Pathway to Develop Antibiotics and Fight Drug Resistant Infections

Other Resource
On Dec. 12, 2013, a bipartisan bill was introduced in the U.S. House of Representatives to encourage development of antibiotics for patients with serious or life-threatening bacterial infections. The new legislation would direct the U.S. Food and Drug Administration, or FDA, to approve new antibiotics and antifungal drugs for specific, limited populations of patients who have infections for which few or no suitable options exist. More

To Take on Superbugs, Prime the Antibiotics Pipeline


In the State of the Union address, President Barack Obama recognized the need to “stay ahead of drug-resistant bacteria” and that developing therapies to fight these threats is an opportunity for American innovation and discovery. The threat of drug-resistant bacteria is real, and the need for antibiotic development clear.


MRSA, Football, and Industrial Farms

MRSA, or methicillin-resistant Staphylococcus aureus, is a type of bacteria that can infect a person’s skin, bones, lungs, heart, brain, and blood. Unlike common staph, MRSA does not respond to traditional antibiotics such as penicillin, making it more difficult and costlier to treat, and more lethal.

Superbug Showdown

Like rivals on the gridiron, superbugs and antibiotic drugs are battling for supremacy. Check out the players on Team Antibiotic and Team Superbug. More

Biocentury: Reps. Introduce Bill for Antibiotic Approval Pathway, Breakpoints

Media Coverage

A bipartisan group of representatives introduced in the U.S. House of Representatives a bill that would create an accelerated approval pathway for antibiotics and antifungals for use in limited populations and would update the criteria that HHS uses to determine breakpoints for drugs.


Letter from Pew Thanking Representatives Gingrey and Green for Leadership on New Antibiotics Legislation

Issue Brief
Representatives Phil Gingrey (R-GA) and Gene Green (D-TX) introduced legislation intended to bring antibiotics to patients with few other treatment options. In a letter, Pew called the bill, named the Antibiotic Development to Advance Patient Treatment (ADAPT) Act, “a welcome step towards establishing a new regulatory pathway to bring desperately-needed antibiotics to the patients who need them the most.” More

Getting Smart is a Group Effort: Addressing the Crisis of Antibiotic Resistance

More and more, we hear about drug-resistant bacteria—superbugs that few, if any, available therapies can kill. Recently, the Centers for Disease Control and Prevention, or CDC, released a report warning that infections from these pathogens result in at least 2 million illnesses and 23,000 deaths every year in the United States. More

Washington Post: ‘Nightmare’ Bacteria are Real, and the U.S. Needs to Act Fast


Last spring, Arjun Srinivasan, an associate director of the CDC, delivered a presentation to state health officials with some alarming information. Before the year 2000, he said, it was rare to find cases of bacteria resistant to carbapenems, a class of powerful, last-resort antibiotics. But by February 2013 they had been seen in almost every state. On March 5, Thomas Frieden, director of the CDC, issued a public warning about “nightmare” bacteria, a family of germs known as CREs. They can kill up to half the patients who get bloodstream infections from them, resist most or all antibiotics and spread resistance to other strains.